Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, it’s a little over a week old. It is clear in tone statement that the testing has been done by now.
I would like to know if this APDN test kit is significantly better than the ones being used.
The company has already applied for rapid deployment with the FDA.
Yesterday: “Preliminary animal test results from the plasmid-based vaccine templates, from which Applied DNA’s linear DNA-based vaccine constructs were manufactured at scale, were immunogenic and induced a strong production of antibodies across all five vaccine candidates,” said Dr. Luigi Aurisicchio, CEO and CSO of Takis Biotech.“
Production of diagnostics kit should begin next week. I believe this is the fastest turnaround for any sample test.
) to validate and implement the Company’s patent-pending nucleic acid diagnostic (LineaCOVID-19TM) to detect and quantify in diagnostic samples the presence of SARS-CoV-2, the virus that causes the disease, COVID-19. Validation is expected to begin immediately with results to be used to support the Company’s application to the U.S. Food and Drug Administration (FDA) before the end of April 2020 for Emergency Use Authorization (EUA).
Great news. I think the human testing will be done now soon. They will speed this process up to warp .
Posted on March 24, 2020:
we are in the process of manufacturing kits for validation at hospitals both in New York State and Italy,” stated said Dr. James Hayward, president and CEO of Applied DNA. “
The tests of the covid scanners in Italy and New York should have been completed within these last two weeks. Where are the results???
Check Sabby’s investment portfolio.
I’m quite sure they play this game with a lot of pharma stocks.
I wasn’t aware that warrants could be used in stock manipulation.
From the available information, it appears that APDN/Takis stands a good chance of having the human trials sped up. Also, the vaccine can be easily modified to future viral outbreaks.
This looks good.
I think the Abbot Labs covid 19 tester put the stake thru APDN.
Also, Takis is working with the EU health authorities in Italy for a vaccine, not a treatment
It looks like Hayward just had his company trashed by Abbott Labs and their rapid reader.
Once again.
Thx. It looks lovely me Takis will have the major EU research institute pushing the four vaccines forward at unheard of speed.
The human clinicals might already be underway.
APDN did state that the vaccine can be rapidly changed to meet the expected mutations.
Thx. It looks lovely me Takis will have the major EU research institute pushing the four vaccines forward at unheard of speed.
The human clinicals might already be underway.
APDN did state that the vaccine can be rapidly changed to meet the expected mutations.
To note:
“we are in the process of manufacturing kits for validation at hospitals both in New York State and Italy,”
When Sabby cashes out, and there is more good news.
I think all the short positions are Sabby and the always hold bank enough shares to cover their position.
They’ve been doing this for years now.
Considering Tyne, Takis a d the recent major pharmaceutical contract, this stock should have popped.
Sabby just has too much stock and warrants. They know how to suck and cover.
Considering Tyne, Takis a d the recent major pharmaceutical contract, this stock should have popped.
Sabby just has too much stock and warrants. They know how to suck and cover.
If you think about it in a timeline perspective, both the Takis vaccine and the test kit are too late.
I believe that new contract is one of fourteen they will be getting per Hayward on the last quarter call in.
Takis is also a startup tortilla chip company.
They do have a go fund me page.
Don’t think this will work.
One thing’s for sure. There aren’t many places to make a buck in this marketplace.
Any company that looks good/ undervalued should do well ultimately.
The vaccine that works is the big If. Also, the one that can be produced the fastest.
I think APDN/Takis might just have a leg up here.
I’m not usually bullish, but this looks good to me.
Yes, a 20% drop in a vaccine stock is remarkable.
Just remember that Sabby was once again a major buyer during the last fund raiser.
They buy and short their own stock. I think this is the third time they’ve done this
Since APDN/Hayward personally met with the Presy, I expect there will be significant research funds coming from this 12 billion package.
This wild fluctuation is the result of manipulation by Sabby I believe.
I could be wrong, but I believe this is the third or fourth time Sabby has bought in and dumped their shares.
You’d have to have an in depth knowyof how they make money on fluctuation in pps.
Everyone knew this would happen, no matter what the news. Sabby bought back in at the last offering.
They short their own stock, then dump and hold the warrants. They can keep this up for extended periods of trading days. You see, Sabby is not really an investment firm. They are a Quant that makes money on small fluctuations.
Applied DNA Sciences (APDN) Enters Multi-Year Contract with Nutrition21
February 19, 2020 10:34 AM
Applied DNA Sciences, Inc. (NASDAQ: APDN) and Nutrition21, LLC announce the successful implementation of Applied DNA’s CertainT authenticity and traceability solution for Nutrition21’s leading sports supplement ingredient, Nitrosigine®. After extensive product development, testing and lab-to-production scaleup, both a multi-year Master Services Agreement and a Trademark Licensing Agreement (the “Agreements”) were signed to cover commercial production of Nitrosigine, as well as potential expansion to other products within the Nutrition21 portfolio. Separately, a Broker Agreement was also signed between the parties to enable Nutrition21 to represent Applied DNA’s CertainT platform throughout its extensive network in the dietary supplement market.
Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China
January 30, 2020
Agreement will facilitate clinical trial translations in China
PLYMOUTH MEETING, Pa., Jan. 30, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected thousands more in China to date. Inovio recently announced that it is developing INO-4800 through Phase 1 human testing in the U.S. to evaluate safety and immunogenicity with the support of an initial grant up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI).
Inovio plans to rapidly develop INO-4800 against the new coronavirus and has already started preclinical testing and preparations for clinical product manufacturing. The goal of this collaboration is to leverage Advaccine's expertise to run a Phase 1 trial in China in parallel with Inovio's clinical development efforts in the U.S. Inovio and Advaccine will also work together to attract additional grant funding and further collaborations with larger vaccine companies in China to increase the speed of future testing of INO-4800.
An American biotech company says it created a coronavirus vaccine three hours after getting access to the virus' genetic sequence in mid-January, and now scientists are racing to get the vaccine on the market in record time.
Inovio Pharmaceuticals is based in Pennsylvania, but scientists in its laboratory in San Diego made the discovery.
I don’t get the volume. Nearly all the available shares traded on Friday.
That doesn’t seem possible.
I think the Grossman’s and possibly the Coca Cola connection.
Somebody’s bought half the shares already
What’s all this premarket buying. Did anyone listen to the meeting??
Right Shark. And when Hayward sets up these investors conferences, it can only get worse.
He barely finished raising 12 million, then sets up an investor conference.
No end.
To me, that’s not good.
Thanks Rode. That is remarkable.
I just don’t think Colorcon could offer it to Pharmaceuticals unless all the approvals are in place.
Jmho.
Why any additional approvals (if any) were needed is an unknown.
Also, we know Colorcon had to do additional testing due to some “problem” they encountered last year. It was ever announced that the additional testy was completed. It looks like several PRs are missing.
I am guessing, from the Colorcon coating articles, that under the new FDA guidelines, the taggants has been accepted as an excipient in pill coatings.
This could be a result of the ongoing dialogue Hayward is alluding to.
As usual, some of the outcomes are embedded in Hayward’s opaque commentary.
No. I expect the same as usual. High hopes followed by crashing disappointments.
Why break a 30 year pattern?